Healthcare >> CEO Interviews >> April 9, 2015

Interview with the President & CEO and Senior Vice President & CFO: Biocept, Inc. (BIOC)

Michael W. Nall
Michael W. Nall is the President and Chief Executive Officer of Biocept, Inc., and a member of its board of directors. He has over 25 years of health care sales and marketing experience, most recently serving at Clarient Diagnostic Services, Inc., in positions of increasing responsibility from 2002 through August 2013, with his last position being General Manager, North American Sales and Marketing. While at Clarient Diagnostic Services, Inc., Mr. Nall was also responsible for leading the team assimilating Clarient Diagnostic Services, Inc. into GE Healthcare after the company was acquired in 2010. From 1988 until joining Clarient Diagnostic Services, Inc., Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems. He received a Bachelor of Science in business administration from Central Missouri State University, now known as the University of Central Missouri. Profile
Bill Kachioff is Biocept, Inc.’s Senior Vice President of Finance and Chief Financial Officer of Biocept, Inc. He is experienced in corporate finance, investor relations, corporate governance and manufacturing accounting and systems. He has over 20 years of life science industry experience, having most recently served as CFO at Althea Technologies, a pharmaceutical contract manufacturing organization. He was also a CFO Partner with Tatum LLC, a national executive services firm focused on the office of the CFO, where he served a variety of life science industry clients in senior financial management roles. Prior to joining Tatum LLC, Mr. Kachioff was CFO at MicroIslet, a publicly traded biotech company developing cell transplant therapies for insulin dependent diabetes. He was Director of Finance at Cutera, where he helped prepare the company for the commercial launch of its first product and its initial public offering. He has also served in a variety of financial management roles at Coulter Pharmaceutical, Vivus and Abbott Labs. Mr. Kachioff has a B.S. in management from the State University of New York at Buffalo and is a member of the American Institute of Certified Public Accountants and the Association of Bioscience Financial Officers. He began his professional career as an Auditor with Deloitte & Touche LLP. Profile
TWST: Please start, if you would, by telling us about Biocept’s historical beginnings as well as the company’s focus today.

Mr. Nall: To address your second question first,